Emicizumab (ACE910) Shows Promising Results for Treatment of Hemophilia A

This essay was featured in the BloodStream Pod.

    Promising results have been reported in early clinical trials of Emicizumab, otherwise known as ACE910. This subcutaneous therapy is being developed for individuals with hemophilia A, with and without inhibitors. ACE910 has been on a fast-track approval process since September 2015 when it was given breakthrough therapy status by the U.S. Food and Drug Administration. Subsequent study is currently being conducted by the makers of the drug, Tokyo-based Chugai Pharmaceutical Co. Ltd. Its hope is that ACE910 will soon offer a new prophylactic treatment option to individuals with hemophilia A.